Q2
ALEC — Q2 2026 Financial Report Analysis
Alector's Q2 2026 net loss narrowed 24.7% to $23.0M on a 34% cut in operating costs, but revenue fell 57.8% to $3.3M and GSK is ending the partnership, leaving $172.8M of cash to fund a preclinical pipeline.